Volume 97, Issue 1, Pages 1-11 (January 2003)

1 of 18

ABSTRACT

ABSTRACT + REFS

FULL-TEXT PDF (206 KB)

Cost–effectiveness analysis of inhaled corticosteroids in asthma: a review of the analytical standards

Received 16 January 2002; accepted 18 June 2002.

Abstract

Purpose: To determine whether published cost–effectiveness studies on inhaled corticosteroids (ICS) in asthma adhered to basic analytical standards as defined in health economic textbooks and in guidelines assessing and comparing efficacy and safety. Methods: Original cost–effectiveness studies published between 1990 and 2000 in general medical or economic journals were reviewed to assess the adherence to five fundamental methodological principles: (1) design of the study, (2) choice of perspective and corresponding costs, (3) choice of outcome measure, (4) marginal cost analysis, and (5) sensitivity analysis and discussion about external validity. For each principle, the studies were ranked as high, medium or low quality. Results: Most of the 18 studies included were ranked medium on the first two principles. The studies adhered to a higher degree to the remaining three principles. Only three studies were high ranked in all five principles. The number of principles fulfilled increased over time. Studies comparing pharmaceutical products from competing companies were typically short-term studies, designed for other purposes than health economic analyses, and, in general, did not use therapeutically equivalent dosing. Conclusions: Attention should be drawn to the study design, the weak correspondence between perspective and costs, and especially to the impact of bias in health economic results when comparing different doses of ICSs.

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

REFERENCES

1. 1 Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health. 2001;4:225–250. MEDLINE | CrossRef

2. 2 Gerdtham UG, Hertzman P, Boman G, Jönsson B. Impact of inhaled corticosteroids on asthma hospitalization in Sweden. Appl Econ. 1996;28:1591–1599.

3. 3 Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887–891. MEDLINE

4. 4 Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther. 1998;20:567–580. MEDLINE | CrossRef

5. 5 Rutten-van Mölken M, Kerstjens H. Combination of inhaled corticosteroids and β 2-agonists in asthma. Clinical and economic implications. Clin Immunother. 1996;6:489–505.

6. 6 Davis R, McTavish D. Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma. Pharmacoeconomics. 1995;7:457–470. MEDLINE | CrossRef

7. 7 Buxton MJ. Economic evaluation studies in respiratory medicine. Respir Med. 1991;85:43–46. CrossRef

8. 8 Sullivan S, Elixhauser A, Buist AS. National Asthma Education and Prevention Program Working Group report on the cost–effectiveness of asthma care. Am J Respir Crit Care Med. 1996;154:S84–S95.

9. 9 Drummond M, O'Brian B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997;.

10. 10 Gold M, Siegel J, Russel L, Weinstein M. Cost–effectiveness in Health and Medicine. New York: Oxford University Press; 1996;.

11. 11 Johannesson M. Theory and Methods of Economic Evaluation of Health Care. Dordrecht: Kluwer Academic Publishers; 1996;.

12. 12 Spilker B. Developing guidelines for pharmacoeconomic trials. In: Spilker B editors. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996;p. 1123–1130.

13. 13 Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ. 1996;5:279–296. MEDLINE

14. 14 Rovira, J, HARMET—The harmonisation by consensus of the methodology for economic evaluation of health care technologies in the European union, September 1997

15. 15 Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52:1–34. MEDLINE

16. 16 Boulet L-P, Cockcroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. Comparative assessment of safety and efficacy of inhaled corticosteroids: report of a committee of the Canadian Thoracic Society. Eur Respir J. 1998;11:1194–1210. MEDLINE | CrossRef

17. 17 Beasley R, Sterk PJ, Kerstjens H AM, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J. 2001;17:579–580. MEDLINE | CrossRef

18. 18 Swedish Council on Technology Assessment in Health Care (SBU), Behandling av astma och KOL. En systematisk kunskapsöversikt, 151, 2000

19. 19 Barnes PJ, Jönsson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636–642. MEDLINE | CrossRef

20. 20 Weiss K, Sullivan S. The economic costs of asthma. A review and conceptual model. Pharmacoeconomics. 1993;4:14–30. MEDLINE | CrossRef

21. 21 Pearson MG, Johnson FN. Pharmacoeconomic aspects of fluticasone propionate in the treatment of asthma. Rev Contemp Pharmacother. 1998;9:591–599.

22. 22 Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: benefits and risks. Semin Respir Crit Care Med. 1998;19:625–646. CrossRef

23. 23 Sullivan S, Weiss K. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol. 2001;107:203–210. Abstract | Full Text | Full-Text PDF (92 KB) | CrossRef

REFERENCES FOR THE 18 REVIEWED ARTICLES

A1. 1. Campbell LM, Simpson RJ, Turbitt ML, Richardson P DI. A comparison of the cost effectiveness of budesonide 400 μg/day and 800 μg/day in the management of mild-to-moderate asthma in general practice. Br J Med Econ. 1993;6:67–74.

A2. 2. Connett GJ, Lenney W, McConchie SM. The cost effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ. 1993;6:127–134.

A3. 3. Rutten-van Mölken M PMH, Van Doorslaer E KA, Jansen M CC, Van Essen-Zandvliet EE, Rutten F FH. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics. 1993;4:257–270. MEDLINE | CrossRef

A4. 4. Booth PC, Capsey LJ, Langdon CG, Wells N EJ. A comparison of the cost–effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ. 1995;8:65–72.

A5. 5. Rutten-van Mölken M PMH, Doorslaer E KA, Jansen M CC, Kertsjens H AM, Rutten F FH. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982.

A6. 6. Booth PC, Wells NE, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics. 1996;10:262–268. MEDLINE | CrossRef

A7. 7. O'Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J. 1996;3:169–175.

A8. 8. Venables TL, McConchie S, Follows R MA. A comparison of the cost–effectiveness of budesonide and fluticasone dry-powder devices in the management of adult asthma. Br J Med Econ. 1996;10:315–323.

A9. 9. Liljas B, Ståhl E, Pauwels RA. Cost–effectiveness analysis of a dry powder inhaler (Turbuhaler) versus pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics. 1997;12:267–277. MEDLINE | CrossRef

A10. 10. Williams J, Richards KA. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/DiskusTM inhaler compared with the Turbohaler™ inhaler in paediatric patients. Br J Clin Pract. 1997;51:147–153. MEDLINE

A11. 11. O'Reilly JF, Weir DC, Banham S, Basran GS, Boyd G, Patel KR. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics?. Respir Med. 1998;92:111–117. Abstract | Full-Text PDF (724 KB) | CrossRef

A12. 12. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost–effectiveness in primary care. Respir Med. 1998;92:351–353. Full-Text PDF (1555 KB) | CrossRef

A13. 13. Steinmetz KO, Volmer T, Trautmann M, Kielhorn A. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Invest. 1998;16:117–123.

A14. 14. Volmer T, Kielhorn A, Weber HH, Weissmann KJ. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naı̈ve patients with moderate asthma. Pharmacoeconomics. 1999;16:525–531. MEDLINE | CrossRef

A15. 15. Miyamoto T, Fujino S, Nakajima S, Tollemar U, Liljas B. Cost–effectiveness of budesonide Turbuhaler in the treatment of mild-to-moderate asthma in Japan. Allergol Int. 1999;48:275–285. CrossRef

A16. 16. Lundbäck B, Pieters W, Johansson G, Palmqvist M, Price M, Sondhi S, et al. Cost–effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma: I–V. Pharmacoeconomics. 1999;16:1–34. MEDLINE | CrossRef

A17. 17. Lundbäck B, Jenkins C, Price M, Thwaites R. Cost–effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma. Respir Med. 2000;94:724–732. Abstract | Full-Text PDF (211 KB) | CrossRef

A18. 18. Stanford RH, Edwards LD, Rickard KA. Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma. Clin Drug Invest. 2000;20:237–244.

IHE, The Swedish Institute for Health Economics, Lund, Sweden

f1 Correspondence should be addressed to: Dr. Ulf Persson, IHE, The Swedish Institute for Health Economics, Box 2127, Se-220 02 Lund, Sweden. Fax: +46-46-12-16-04; E-mail: up@ihe.se

PII: S0954-6111(02)91405-8

doi:10.1053/rmed.2002.1405

1 of 18